Faculty Collaboration Database

EUS-guided fine-needle biopsy sampling of solid pancreatic masses with and without rapid onsite evaluation for commercial next-generation genomic profiling. Gastrointest Endosc 2025 Dec;102(6):855-862.e1

Date

03/24/2025

Pubmed ID

40122217

DOI

10.1016/j.gie.2025.03.1208

Scopus ID

2-s2.0-105004294361 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

BACKGROUND AND AIMS: Although EUS-guided fine-needle biopsy sampling (EUS-FNB) of solid pancreatic lesions with or without the use of rapid onsite evaluation (ROSE) provides a high diagnostic yield, the utility of ROSE for commercial genomic analysis is unclear.

METHODS: A multicenter retrospective review was conducted of consecutive patients where genomic analysis was requested from EUS-FNB of solid pancreatic lesions, performed with 22-gauge fine-needle biopsy (FNB) needles. Data were collected at 2 academic centers, one that routinely uses ROSE to assess adequacy for all EUS-FNB cases (University of California San Francisco, n = 44) and one that does not use ROSE (Washington University, n = 186).

RESULTS: The cohort consisted of 230 patients (mean age, 67.3 ± 9.8 years; 52.6% women). There were no significant differences between patient and tumor characteristics or locations in the 2 groups. Adverse events were uncommon and similar between the groups (1.6% vs 0%). Adequacy for genomic evaluation was high and similar between those cases without and with ROSE (159/186 [85.5%] vs 39/44 [88.6%], P = .8). Genomic analysis resulted in potentially actionable mutations in a similar number of cases without and with ROSE (18.3% vs 15.9%, P = .82). However, compared with FNB sampling without ROSE, FNB sampling with ROSE required more than double the procedure time (mean, 21.1 ± 10 minutes vs 49.7 ± 20.6 minutes; P < .001) and a significantly higher number of median needle passes (3 [IQR, 2-3] vs 4 [IQR, 3-4], P < .001).

CONCLUSIONS: Although EUS-FNB with ROSE did not have a significantly different adequacy for commercial genomic analysis compared with EUS-FNB without ROSE, it required significantly more procedure time and needle passes.

Author List

Dbouk M, Davis BG, Peller M, Sloan E, Hollander T, Reyes-Genere JP, Bazarbashi A, Ismail MK, Lang G, Kushnir V, Early D, Ballentine S, Dai SC, Kouanda A, Das KK

Author

Matthew T. Peller MD Assistant Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Aged, 80 and over
Carcinoma, Pancreatic Ductal
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Female
Humans
Male
Middle Aged
Neuroendocrine Tumors
Pancreatic Neoplasms
Retrospective Studies